Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
Now showing 1 - 6 of 6
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Global multi-societies endorsement of the MAFLD definition
    (2024)
    Alboraie, Mohamed
    ;
    Tanwandee, Tawesak
    ;
    Xu, Xiaoyuan
    ;
    Nikolova, Dafina
    ;
    Estupiñan, Enrique Carrera
    Scopus© Citations 4
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
    (Springer Science and Business Media LLC, 2020-09)
    Sarin, Shiv Kumar
    ;
    Choudhury, Ashok
    ;
    Lau, George K
    ;
    Zheng, Ming-Hua
    ;
    Ji, Dong
    BACKGROUND AND AIMS: COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis. METHODS: Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19. RESULTS: Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1-3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9-38.8), p = 0.002] predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p < 0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC 0.94, HR = 19.2 (95 CI 2.3-163.3), p < 0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis patients. CONCLUSIONS: SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.
    Scopus© Citations 227
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
    (2022-04)
    Lau, George
    ;
    Yu, Ming-Lung
    ;
    Wong, Grace
    ;
    Thompson, Alexander
    ;
    Ghazinian, Hasmik
    Scopus© Citations 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.
    (2025-02)
    Choudhury, Ashok
    ;
    Kulkarni, Anand V
    ;
    Arora, Vinod
    ;
    Soin, A S
    ;
    Dokmeci, Abdul Kadir
    Scopus© Citations 102
  • Some of the metrics are blocked by your 
    Item type:Publication,
    The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    (2025-04)
    Eslam, Mohammed
    ;
    Fan, Jian-Gao
    ;
    Yu, Ming-Lung
    ;
    Wong, Vincent Wai-Sun
    ;
    Cua, Ian Homer
    Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.
    Scopus© Citations 210
  • Some of the metrics are blocked by your 
    Item type:Publication,
    APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
    (2024-12)
    Lau, George
    ;
    Obi, Shuntaro
    ;
    Zhou, Jian
    ;
    Tateishi, Ryosuke
    ;
    Qin, Shukui
    In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia-Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?
    Scopus© Citations 96